Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

127.31 +2.95 (+2.37%)

Official Closing Price Updated: 7:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

52 53 Next >

US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact ↗

January 31, 2025

US stock futures climbed on Friday, pointing to a third straight week of gains fueled by strong corporate earnings.

Via Benzinga

Novartis Q4: Earnings Beat Estimates, CEO Dismisses Entresto Patent Expiration Worries ↗

January 31, 2025

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's U.S. patent expiration while projecting continued growth in 2025.

Via Benzinga

Topics Earnings Intellectual Property

When you look at NYSE:NVS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

January 31, 2025

NOVARTIS AG-SPONSORED ADR is a hidden gem, featuring undervaluation and robust fundamentals. NYSE:NVS showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

Earnings Scheduled For January 31, 2025 ↗

January 31, 2025

Via Benzinga

Uncovering Dividend Opportunities with NYSE:NVS. ↗

January 27, 2025

Uncovering Dividend Opportunities with NOVARTIS AG-SPONSORED ADR (NYSE:NVS).

Via Chartmill

AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings? ↗

January 30, 2025

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

Via Benzinga

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders ↗

January 29, 2025

Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.

Via Benzinga

Topics Government

AI Pharma: 2 Paths to AI-Powered Drug Investment

January 28, 2025

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

Via MarketBeat

Topics Artificial Intelligence

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗

January 22, 2025

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Via Benzinga

Balancing Dividends and Fundamentals: The Case of NYSE:NVS. ↗

January 03, 2025

Exploring NOVARTIS AG-SPONSORED ADR (NYSE:NVS)'s dividend characteristics.

Via Chartmill

Why the dividend investor may take a look at NYSE:NVS. ↗

December 13, 2024

Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) qualifies as a good dividend investing stock.

Via Chartmill

Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases ↗

January 22, 2025

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Via Benzinga

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug ↗

January 16, 2025

Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients.

Via Benzinga

Don't overlook NYSE:NVS—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

January 10, 2025

Investors should take notice ofNOVARTIS AG-SPONSORED ADR (NYSE:NVS)—it offers a great deal for the fundamentals it presents.

Via Chartmill

Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development ↗

January 08, 2025

Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones.

Via Benzinga

CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices ↗

January 06, 2025

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions.

Via Benzinga

Topics Lawsuit

2 Dividend Stocks to Buy and Hold Forever ↗

December 01, 2024

Via The Motley Fool

Exploring NYSE:NVS's dividend characteristics. ↗

November 22, 2024

Is NOVARTIS AG-SPONSORED ADR (NYSE:NVS) suited for dividend investing?

Via Chartmill

Will This Major Pharmaceutical Stock Announce a Stock Split in 2025? ↗

December 30, 2024

Via The Motley Fool

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services ↗

December 19, 2024

U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.

Via Benzinga

For those who appreciate value investing, NYSE:NVS is a compelling option with its solid fundamentals. ↗

December 19, 2024

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

December 18, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

December 18, 2024

From FN Media Group LLC

Via GlobeNewswire

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗

December 13, 2024

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.

Via Benzinga

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug ↗

December 10, 2024

The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval.

Via Investor's Business Daily

Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder ↗

December 06, 2024

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks.

Via Benzinga

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst ↗

December 03, 2024

Janux Therapeutics reports updated clinical data for JANX007, highlighting significant efficacy, safety, and durability in advanced prostate cancer patients.

Via Benzinga

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program ↗

December 02, 2024

PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up to $2.9 billion, including milestones and royalties.

Via Benzinga

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone ↗

December 02, 2024

The deal focuses on the company's treatment for Huntington's disease.

Via Investor's Business Daily

Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline ↗

November 21, 2024

Novartis increases mid-term sales growth forecast to 6% CAGR for 2023-2028, citing robust growth drivers, upcoming launches, and a promising innovation pipeline.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

52 53 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today